Crizotinib in ALK Rearranged Non-small-cell Lung Cancer (SPECIALK)

  • days left to enroll
  • participants needed
  • sponsor
    Fondazione Ricerca Traslazionale
Updated on 2 March 2022
lung cancer
stage iv non-small cell lung cancer
lung carcinoma


This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.


Primary efficacy objective:

To assess the efficacy of crizotinib in real life setting

Secondary objectives:

  1. To evaluate the therapeutic response to crizotinib-based treatment
  2. To identify additional biomarkers selectively present in the ALK positive population
  3. To assess the safety of crizotinib (250 mg/bid) in the treatment of NSCLC in real life setting

Non-small-cell Lung Cancer (NSCLC) remains the leading cause of cancer death in Western Countries. Identification of anaplastic lymphoma kinase (ALK) gene rearrangements reinforced the role of targeted therapies in lung cancer. The EML4-ALK fusion gene is detected in 3-7% of patients with adenocarcinomas of the lung and is associated with specific clinical pathological features, including young age, absent or minimal smoking history and adenocarcinoma histology. However, such clinical features do not properly select patients for ALK inhibitors (ALK-Is) and, consequently, molecular testing is mandatory. Indeed, current guidelines recommend to test ALK rearrangements at diagnosis all patients with advanced lung adenocarcinoma, due to immediate therapeutic implications.

Condition Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Cancer
Clinical Study IdentifierNCT04317651
SponsorFondazione Ricerca Traslazionale
Last Modified on2 March 2022


Yes No Not Sure

Inclusion Criteria

\. Males and Females aged 18 years with diagnosis of advanced or metastatic NSCLC
\. Former participation in the Italian NPU program between December 2010 - April 2013 or receiving crizotinib according to 648 legislative Decrete from April 2013 to February 2015 and thereafter in clinical practice up to December 31st, 2017
\. Ascertained compliance to the Crizotinib therapy as prescribed by the relevant physician
\. ALK rearrangement report including details of method and cutoff used for ALK testing
\. Data on prior therapies
\. Data on toxicity
\. Data on crizotinib therapy efficacy including response to the therapy and survival
\. Data on site of metastases
\. Availability of archival tissue (not mandatory)
\. Signed Informed Consent for alive and contactable patients

Exclusion Criteria

\. Lack of clinical data
\. No evidence of ALK rearrangemement
\. Early death defined as fatal outcome within 30 days since the first crizotinib dose
\. Absence of any radiological assessment
\. No data on crizotinib efficacy including survival
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note